Doxefazepam

Doxefazepam
Clinical data
Routes of
administration		Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismHepatic
Elimination half-life3-4 hours[1]
ExcretionRenal
Identifiers
  • 9-chloro-6-(2-fluorophenyl)-4-hydroxy-2-(2-hydroxyethyl)-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-3-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H14ClFN2O3
Molar mass348.76 g·mol−1
3D model (JSmol)
  • FC1=CC=CC=C1C2=NC(C(N(CCO)C3=C2C=C(C=C3)Cl)=O)O
  • InChI=1S/C17H14ClFN2O3/c18-10-5-6-14-12(9-10)15(11-3-1-2-4-13(11)19)20-16(23)17(24)21(14)7-8-22/h1-6,9,16,22-23H,7-8H2 checkY
  • Key:VOJLELRQLPENHL-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)

Doxefazepam (marketed under brand name Doxans) is a benzodiazepine medication It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It is used therapeutically as a hypnotic.[2] According to Babbini and colleagues in 1975, this derivative of flurazepam was between 2 and 4 times more potent than the latter while at the same time being half as toxic in laboratory animals.[3]

It was patented in 1972 and came into medical use in 1984.[4]

  1. ^ "Doxefazepam". IPCS INTOX. Archived from the original on 24 July 2008.
  2. ^ Rodriguez G, Rosadini G, Sannita WG, Strumia E (1984). "Effects of doxefazepam on normal sleep. An EEG and neuropsychological study". Neuropsychobiology. 11 (2): 133–139. doi:10.1159/000118066. PMID 6483162.
  3. ^ Babbini M, Torrielli MV, Strumia E, Gaiardi M, Bartoletti M, De Marchi F (August 1975). "Sedative-hypnotic properties of a new benzodiazepine in comparison with flurazepam. Pharmacological and clinical findings". Arzneimittel-Forschung. 25 (8): 1294–1300. PMID 241364.
  4. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 539. ISBN 9783527607495.